Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations.
Plasmablastic lymphoma is a relatively new entity that is considered to be a diffuse large B-cell lymphoma with an unique immunophenotype and a predilection for the oral cavity. We present a 50 year-old HIV-positive, bisexual, white male with a CD4 count 300/mm(3) and a viral HIV-RNA polymerase chain reaction (PCR) load of 237 copies/ml, who developed a painful, purple-red mass in the edentulous area of the maxillary right first molar. Erythematous gingival enlargements of the interdental papillae were seen in three of the dental quadrants. In addition, the patient was being managed with antiretroviral therapy and liposomal doxorubicin for recurrent cutaneous Kaposi's sarcoma (KS). Although oral KS was suspected, the gingival lesions were biopsied because they were refractory to chemotherapy and a lymphoma could not be excluded. Histopathologic examination revealed a lymphoid malignant neoplasm, consistent with a plasmablastic lymphoma. Immunoreactivity with vs38c, CD79a, kappa light chain, and IgG was readily identified in tumor cells; while only focal cells expressed CD20 and LCA (CD45RB). CD56, CD3, lambda light chain, and EMA were non-reactive. EBV was detected in the tumor by Southern hybridization, PCR amplification, in situ hybridization for EBER-1 DNA, and immunohistochemistry for latent membrane protein-1. The same tumor was negative for HHV-8 by PCR. Recognition of plasmablastic lymphoma is important, because it represents an HIV-associated malignancy that predominantly involves the oral cavity, may mimic KS and has a poor prognosis.
Flaitz
C M
CM
Department of Stomatology, University of Texas-Houston Health Science Center, Dental Branch, 6516 John Freeman Avenue, Houston, TX 77030, USA. cmflaitz@mail.uth.db.edu
Nichols
C M
CM
Walling
D M
DM
Hicks
M J
MJ
D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D003937:Diagnosis, Differential; D020031:Epstein-Barr Virus Infections / Q000150:complications; D017809:Fatal Outcome; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D012514:Sarcoma, Kaposi / Q000175:diagnosis